• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

不可切除胆管癌治疗的最新进展

Recent progress in the treatment for unresectable biliary tract cancer.

作者信息

Endo Itaru

机构信息

Department of Gastroenterological Surgery Yokohama City University Graduate School of Medicine Yokohama Japan.

出版信息

Ann Gastroenterol Surg. 2023 Jun 29;7(4):540-542. doi: 10.1002/ags3.12710. eCollection 2023 Jul.

DOI:10.1002/ags3.12710
PMID:37416743
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10319608/
Abstract

Recent changes in the treatment of unresectable BTC have been remarkable. More recently, triple combination therapy with GC and S-1 (GCS) and GC and nab-Paclitaxel was used. Also, immune checkpoint inhibitors have been increasingly used for BTC.

摘要

不可切除性胆管癌（BTC）治疗方面的近期变化显著。最近，采用了吉西他滨（G）和顺铂（C）与S-1的三联联合疗法（GCS）以及吉西他滨（G）和顺铂（C）与白蛋白结合型紫杉醇的三联联合疗法。此外，免疫检查点抑制剂在BTC治疗中的应用也越来越多。

相似文献

1
Recent progress in the treatment for unresectable biliary tract cancer.不可切除胆管癌治疗的最新进展
Ann Gastroenterol Surg. 2023 Jun 29;7(4):540-542. doi: 10.1002/ags3.12710. eCollection 2023 Jul.
2
Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review.吉西他滨联合顺铂化疗治疗初始不可切除的晚期胆管癌的转化手术：1例病例报告及文献综述
Int Cancer Conf J. 2022 Mar 29;11(3):188-195. doi: 10.1007/s13691-022-00545-y. eCollection 2022 Jul.
3
Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancers.吉西他滨和顺铂联合S-1治疗及后续转化手术对初始不可切除的上段胆管癌的预后影响
Surg Today. 2025 Mar;55(3):351-359. doi: 10.1007/s00595-024-02912-z. Epub 2024 Aug 13.
4
Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.单中心经验：吉西他滨联合顺铂方案作为吉西他滨联合替吉奥方案二线治疗失败的不可切除胆道癌患者的治疗选择：一项前瞻性可行性研究。
Cancer Chemother Pharmacol. 2018 May;81(5):949-955. doi: 10.1007/s00280-018-3566-z. Epub 2018 Mar 28.
5
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.纳米白蛋白结合型紫杉醇联合吉西他滨-顺铂治疗晚期胆管癌患者的真实世界疗效和安全性：一项多中心回顾性分析
Ther Adv Med Oncol. 2021 Aug 7;13:17588359211035983. doi: 10.1177/17588359211035983. eCollection 2021.
6
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).随机 III 期研究：吉西他滨、顺铂加 S-1 对比吉西他滨、顺铂治疗晚期胆道癌（KHBO1401- MITSUBA）。
J Hepatobiliary Pancreat Sci. 2023 Jan;30(1):102-110. doi: 10.1002/jhbp.1219. Epub 2022 Aug 9.
7
Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.复发性胆管癌患者的预后优于不可切除疾病患者：对接受姑息化疗的晚期胆管癌患者的多机构经验进行回顾性分析。
J Hepatobiliary Pancreat Sci. 2014 Feb;21(2):98-104. doi: 10.1002/jhbp.2. Epub 2013 Jun 20.
8
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.PD-L1、肿瘤突变负荷、微卫星不稳定性及其他胆管癌中免疫检查点抑制剂反应的预测指标
Cancers (Basel). 2021 Feb 1;13(3):558. doi: 10.3390/cancers13030558.
9
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.吉西他滨联合顺铂化疗后序贯替吉奥胶囊治疗晚期胆道癌的有效性和安全性。
Invest New Drugs. 2021 Oct;39(5):1399-1404. doi: 10.1007/s10637-021-01098-2. Epub 2021 Apr 9.
10
Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma.免疫检查点抑制剂致晚期胆道癌患者肝损伤的临床特征。
Invest New Drugs. 2023 Oct;41(5):719-726. doi: 10.1007/s10637-023-01391-2. Epub 2023 Aug 17.

引用本文的文献

1
Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies.胆管癌的基因组图谱及相应的靶向治疗策略。
Int J Clin Oncol. 2025 Apr 25. doi: 10.1007/s10147-025-02761-x.

本文引用的文献

1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
2
Current progress in perioperative chemotherapy for biliary tract cancer.胆道癌围手术期化疗的当前进展
Ann Gastroenterol Surg. 2023 May 16;7(4):565-571. doi: 10.1002/ags3.12691. eCollection 2023 Jul.
3
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗联合吉西他滨和顺铂与单纯吉西他滨和顺铂治疗晚期胆道癌患者的比较（KEYNOTE-966）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
4
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.特泊替尼联合仑伐替尼和 GEMOX 作为一线治疗晚期肝内胆管癌的方案具有广阔前景：一项单中心、单臂、Ⅱ期研究。
Signal Transduct Target Ther. 2023 Mar 17;8(1):106. doi: 10.1038/s41392-023-01317-7.
5
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).随机 III 期研究：吉西他滨、顺铂加 S-1 对比吉西他滨、顺铂治疗晚期胆道癌（KHBO1401- MITSUBA）。
J Hepatobiliary Pancreat Sci. 2023 Jan;30(1):102-110. doi: 10.1002/jhbp.1219. Epub 2022 Aug 9.
6
Nivolumab for treating patients with occupational cholangiocarcinoma.尼伏单抗治疗职业性胆管癌患者。
J Hepatobiliary Pancreat Sci. 2022 Nov;29(11):1153-1155. doi: 10.1002/jhbp.1215. Epub 2022 Aug 8.
7
Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis.辅助 S-1 对比吉西他滨治疗淋巴结阳性肝门部胆管癌：一项倾向评分调整分析。
J Hepatobiliary Pancreat Sci. 2021 Sep;28(9):716-726. doi: 10.1002/jhbp.1005. Epub 2021 Jun 22.
8
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.吉西他滨联合 S-1 对比吉西他滨联合顺铂治疗晚期/复发性胆道癌：FUGA-BT（JCOG1113）随机 III 期临床试验。
Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402.
9
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.尼伏鲁单抗单药治疗或联合顺铂和吉西他滨治疗不可切除或复发性胆道癌的日本患者：一项非随机、多中心、开放标签、1 期研究。
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621. doi: 10.1016/S2468-1253(19)30086-X. Epub 2019 May 17.
10
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.吉西他滨、顺铂和 nab-紫杉醇治疗晚期胆道癌：一项 2 期临床试验。
JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270.